After his Joining the Munich-based biotech company Thermosome, sets Bavaria Capital continues its investment tour: The venture capital company of the Free State of Bavaria is investing in Cunesoft's seven-figure Series A growth financing.
Cunesoft GmbH, a provider of regulatory master data software for various pharmaceutical industries, has completed a seven-figure Series A investment round. In addition to lead investor Occident Group from Switzerland, Bayern Kapital and High-Tech Gründerfonds, both of which have been on board as investors since October 2014 as part of the seed round, are also participating again.
“The modular SaaS solution offered by Cunesoft is interesting for companies of all sizes and helps customers to remain competitive,”
explains Dr. Georg Ried, Managing Director of Bayern Kapital,
“Cunesoft is in a Growth market on the go, and we're happy to continue supporting that. What makes Cunesoft special is its software solution, which is unique in the industry. Cunesoft is the first to offer a consistent and integrated application from a single source."
International expansion planned
With the new investment, the company wants to be Further accelerate growth and to expand local and international sales – especially in the US and Asia. The software-as-a-service (SaaS) company is already internationally positioned with locations in Germany, France, and India.
"We are very pleased that our seed investors continue to believe in Cunesoft. With the Occident Group, we have now found an internationally networked partner,"
explains Rainer Schwarz, founder and CEO of Cunesoft,
"With the additional capital, we will not only grow geographically but also better target the top 250 pharmaceutical and life science companies. Previously, the focus was on small and medium-sized enterprises."
With additional software modules, the company should also become more interesting for international corporations.
